The Netherlands
Devices for treatment


Sepsis is the primary cause of hospital fatalities in Western nations. Its mortality rate is soaring by an average of 8% annually, and it stands as the most costly hospital condition in the US, accounting for 6% of total expenses and 4% of hospital admissions. Compounded by the escalating threat of antibiotic resistance, conventional sepsis treatments often prove inadequate, resulting in a mortality rate ranging between 20-30%.


There’s a notable opportunity for therapeutic advancements to enhance existing treatment protocols, improving patient outcomes while reducing financial burdens. This demand underscores the potential for innovative interventions to revolutionize sepsis management, particularly those that can seamlessly integrate with current strategies, resulting in superior clinical efficacy and cost-effectiveness.


Sanquin, a leading blood bank in Europe, has developed a patented filtering technology using apheresis to remove pathogens bound to red blood cells, aiming to prevent sepsis progression and support patient recovery. In vitro test with human blood has demonstrated high efficacy across many sepsis-associated pathogens, and adaptable to existing apheresis units with cost-effective filtration materials.


The planned clinical trial aims aims to demonstrate the safety and effectiveness of the system in clinical application before the end of 2024. Safety in sepsis patients will be evaluated based on the occurrence and nature of adverse events related to device usage, while performance will be assessed primarily by the system’s ability to reduce circulating RBC-pathogen complexes by at least 50% in sepsis patients post-treatment and secondarily by observing the effects on speed of patient recovery.

Meet the team

Robin Van Bruggen

Robin van Bruggen


Doctor of Medicine • Department of blood cell research

Taco van der Feltz (1)

Taco van der Feltz

Venture Partner at NLC

Taco joined NLC in 2015 and is a highly international and networked entrepreneur trained as Medical Doctor and Medical Biologist. He is a visionary strategist conversant within and across disciplines. As Venture Partner, Taco focuses on building innovative companies and strengthening NLC’s abilities to bring innovations to healthcare.


Jikke de Jong

Lead Green Health Ventures

Joining NLC from its inception in 2015, Jikke has been serving several roles in the organisation. With an MSc in Science and Innovation Management, specializing in Life Sciences, her academic background spans technology, innovation, and sustainability, covering diverse areas from finance to drug development. Currently, Jikke oversees NLC's Green Health activities, spearheading efforts to reduce healthcare's environmental impact while enhancing patient care. Her role at NLC include sourcing leads, closing IP deals, building venture teams, and fostering lasting partnerships. Jikke is dedicated to crafting innovative solutions that benefit both patients and the planet.